DGAP-News: Xenikos to participate in BIO-Europe(R) 2016 - 22nd Annual International Partnering Conference


DGAP-News: Xenikos B.V. / Key word(s): Conference/Miscellaneous
Xenikos to participate in BIO-Europe(R) 2016 - 22nd Annual International
Partnering Conference

25.10.2016 / 08:00
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

PRESS RELEASE

Xenikos to participate in BIO-Europe(R) 2016 - 22nd Annual International
Partnering Conference

Company to discuss its proprietary immunotherapy T-GuardTM with potential
pharmaceutical partners

Final results of Phase 1/2 trial with T-Guard(TM) against acute graft-
versus-host disease expected in first half of 2017

Nijmegen, the Netherlands, October 25, 2016 - Xenikos B.V., focused on the
development of innovative immunotherapies for the treatment of patients
suffering from serious immune diseases or rejection after transplantation,
announced today that it will participate in the upcoming BIO-Europe(R) 2016
- 22nd Annual International Partnering Conference being held November 7-9,
2016 in Cologne, Germany. At the conference, Xenikos will meet with
pharmaceutical companies to discuss its product candidate, T-GuardTM, which
is in Phase 1/2 testing for the treatment of steroid-resistant acute graft
versus host disease (GVHD). T-Guard(TM) consists of a combination of two
toxin-loaded anti-T-cell antibodies and has shown promise as a therapeutic
tool for safely and swiftly resetting the body's immune system in T-cell-
mediated diseases.

Ypke van Oosterhout, Chief Executive Officer of Xenikos, said: "We look
forward to discussing our promising product candidate T-GuardTM with
potential partners at this important event. We believe this to be the ideal
time for partnering discussions given the last patient in an ongoing Phase
I/II trial has just been treated with our product and final results are
expected as early as the first half of 2017. We have seen a high level of
interest in our Company and T-Guard(TM) by a number of pharmaceutical
companies already and look forward to evaluating further development
opportunities, as we strongly believe that this innovative approach can
help restore patients' health and save lives."

Companies interested in meeting with Xenikos at BIO-Europe are asked to
request a meeting through the event's partneringONE(R) online system or to
contact Ypke van Oosterhout at y.vanoosterhout@xenikos.com. In addition,
the Company will also be available to the media for interviews and
background discussions.

About BIO-Europe(R)
BIO-Europe is the preeminent partnering conference for the life sciences,
bringing together international decision makers from the biotechnology,
pharmaceutical and financial sectors, offering networking opportunities,
workshop and panel participation, a high profile exhibition, and private,
prescheduled one-on-one meetings. The BIO-Europe 2016 partnering event is
expected to draw over 3,500 industry attendees for three days of high level
networking, representing upwards of 1,900 companies from over 50 countries.

About T-Guard(TM)
T-Guard(TM) is currently in development by Xenikos for the treatment of
certain life-threatening immune conditions, such as transplant-related
rejection, graft versus host disease (GVHD), acute solid-organ rejection
and several severe autoimmune diseases. T-Guard(TM) consists of a
combination of two toxin-loaded anti-T-cell antibodies and shows promise as
a therapeutic tool for safely and swiftly resetting the body's immune
system in T-cell-mediated diseases. Once injected into the body, T-
Guard(TM) specifically identifies and eliminates adult T cells, with a
strong preference for the activated ones. The particular combination of
immunotoxins used to construct T-Guard(TM) was designed to provide a unique
blend of synergistic efficacy, narrow specificity and multiple, gentle
mechanisms of action. In preclinical testing, T-Guard(TM) was shown to be
highly effective in killing activated T cells and to act through apoptotic
(programmed cell death) mechanisms, which are associated with minimal side
effects. T-Guard's targeted action is believed to leave patients less
vulnerable to opportunistic infections when compared to historical controls
of institutional standard of care. In a clinical proof-of-concept study, T-
Guard(TM) appeared to be well tolerated with strong biological and clinical
responses observed. T-Guard(TM) is currently in clinical Phase 1/2 testing
in Europe for the second-line treatment of steroid-resistant acute GVHD.
The primary endpoint of the study is response rate at 28 days. Other
endpoints include overall survival at 180 days; safety and tolerability are
also being evaluated. Preliminary results from this study showed strong
clinical responses and indicated a substantial improvement over published
institutional historical survival rates, with a well-manageable side effect
profile without severe infusion reactions. T-Guard(TM) has been granted
Orphan Drug Designation in both the EU and US. The Company plans to
initiate a pivotal clinical study in the second half of 2017.

About Xenikos B.V.
Xenikos B.V. is developing new, innovative immunotherapies to help restore
patients' health and save lives. It is developing new therapies based on
the action of conjugated antibodies that enables patients suffering from
serious immune diseases or rejection after transplantation to reset their
immune systems quickly and efficiently. Its lead product candidate T-
GuardTM is currently being developed for the second-line treatment of
steroid-resistant acute GVHD. Further information is available at
www.xenikos.com.

For further information, please contact:

<pre>
Corporate contact:                  Media contact:

Xenikos B.V.                        MC Services AG
Ypke van Oosterhout                 Dr. Solveigh Mähler
Chief Executive Officer             Phone: +49 211 529 252 19
Phone: +31 24 3000100               Email: solveigh.maehler@mc-services.eu
Mobile: +31 6 11017611
Email: y.vanoosterhout@xenikos.com  For US inquiries:
                                    Laurie Doyle
                                    Phone: +1 339 832 0752
                                    Email: laurie.doyle@mc-services.eu
</pre>


---------------------------------------------------------------------------

25.10.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------

513975 25.10.2016